Stryker agreed to acquire Amplitude Vascular Systems, adding hydraulic intravascular lithotripsy technology for calcified peripheral arterial disease. The deal expands Stryker's peripheral vascular portfolio and supports its medtech focus. Shares are considered undervalued, trading around $313.5, as the company strengthens offerings in a challenging disease area.